

Product

CPR Invest - B&W European Strategic Autonomy HY 2032 - A CZKH Acc

A Sub-Fund of CPR Invest

LU3516173575 - Currency: CZK

This Sub-Fund is authorised in Luxembourg.

Management Company: CPR Asset Management (thereafter: "we"), a member of the Amundi Group of companies, is authorised in France and regulated by the Autorité des marchés financiers.

The AMF is responsible for supervising CPR Asset Management in relation to this Key Information Document.

For more information, please refer to www.cpram.com or call +33 153157000.

This document was published on 30/09/2026.

What is this product?

Type: Shares of a Sub-Fund of CPR Invest, an Undertaking for Collective Investments in Transferable Securities (UCITS), established as a SICAV.

Term: This Sub-Fund matures on 30/01/2032. The Management Company may terminate the fund by liquidation or merger with another fund in accordance with legal requirements.

Objectives: The investment objective is to achieve income and capital appreciation over the recommended holding period (at least 5 years) by building a "buy and watch" diversified credit portfolio, which contributes to the European recovery and resilience.

During the placement period, the Compartment will invest only in bonds, money market instruments, money market UCITS and bank deposits.

On 15 January 2028 (i.e., twelve months following the end of the placement Period), the Compartment will be closed to further subscriptions. This Compartment has been launched on 1st October 2026 and will mature on 30 January 2032 (the "Maturity Date").

The « buy and watch » credit strategy is a low turnover strategy that invests primarily in a diversified portfolio of debt securities with the intention to hold them until their respective maturity. However, the portfolio manager closely monitors the portfolio securities and may decide to replace some of them in the event of opportunities or risk of defaults.

The Compartment is a financial product that promotes ESG characteristics pursuant to Article 8 of the Disclosure Regulation. The Compartment seeks to achieve an ESG score of its portfolio greater than that of ICE BOFA BB-B EURO HIGH YIELD CONSTRAINED INDEX.

To achieve this, the Compartment aims to select securities of companies active in economic sectors that have a direct or indirect link with Europe's resilience and/or that contribute to Europe's economic autonomy and development such as Food, Healthcare, Industrials, Energy, Digital, Defense... The Compartment is actively managed and is not managed in reference to a benchmark.

The Compartment is mainly invested in Euro and US dollar-denominated bonds (including green bonds) issued by public (government, supranational, local/international public bodies) and private issuers incorporated, headquartered or having their principal business activities in the European Economic Area (EEA) as well as in the UK and Switzerland. The Compartment is managed within a range of modified duration between [0; +5].

The Compartment can be invested up to 100% of its assets in securities rated "Speculative Grade" at the time of their acquisition. The Compartment can also be invested in securities rated "Investment Grade". At the launch of the strategy, under normal market circumstances, the average rating of the Compartment's portfolio is expected to be between 'BB-' and 'BB+' (as rated by S&P/Fitch).

The Compartment's investments may include, but are not limited to, subordinated bonds, senior bonds, preferred securities, corporate hybrid bonds and perpetual bonds (within a limit of 25% of its assets for perpetual bonds). The Compartment may invest up to 70% in subordinated bonds.

The Compartment may also invest up to 20% of its assets in emerging markets, belonging to the EEA.

The Compartment may invest up to 25% of its assets in callable bonds maturing after the Maturity Date provided, they have a first call date before the Compartment's Maturity Date.

The Compartment may invest up to 10% of its assets in contingent convertible bonds (CoCos).

The Compartment will not actively purchase Distressed Default Securities; however, the Compartment might hold such securities in case of a rating downgrade of an investment that is already part of the compartment holdings, provided that it is deemed in the best interests of shareholders. In this context, the Compartment's exposure to Distressed Default Securities should not exceed 5% of the Compartment's assets.

Derivative instruments will be used for hedging, arbitrage, exposure purposes and/or efficient portfolio management.

Intended Retail Investor: This product is intended for investors, with a basic knowledge of and no or limited experience of investing in funds seeking to increase the value of their investment over the recommended holding period with the ability to bear losses up to the amount invested.

Redemption and Dealing: Shares may be sold (redeemed) as stated in the prospectus at the respective dealing price (net asset value). Further details are provided in the CPR Invest prospectus.

Distribution Policy: As this is a non-distributing share class, investment income is reinvested.

More Information: You may get further information about the Sub-Fund, including the prospectus, and financial reports which are available at and free of charge on request from: CPR Asset Management at 91-93, boulevard Pasteur – CS 61595 – 75730 Paris Cedex 15.

The Net Asset Value of the Sub-Fund is available on www.cpram.com

Depositary: CACEIS Bank, Luxembourg Branch.

What are the risks and what could I get in return?

RISK INDICATOR



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movement in the markets or because we are not able to pay you.

We have classified this product as 2 out of 7, which is a low risk class. This rates the potential losses from future performance at a low level, and poor market conditions are very unlikely to impact our capacity to pay you.

Additional risks: Market liquidity risk could amplify the variation of product performances.

This product does not include any protection from future market performance so you could lose some or all of your investment. Beside the risks included in the risk indicator, other risks may affect the Sub-Fund’s performance. Please refer to the CPR Invest prospectus.

PERFORMANCE SCENARIOS

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Sub-Fund over the last 10 years. Markets could develop very differently in the future. The stress scenario shows what you might get back in extreme market circumstances.

What you get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

Recommended holding period until the product matures : 5 years Investment CZK 250,000			
Scenarios		If you exit after	
		1 year	5 years
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress Scenario	What you might get back after costs	CZK181,750	CZK172,750
	Average return each year	-27.3%	-7.1%
Unfavourable Scenario	What you might get back after costs	CZK181,750	CZK210,500
	Average return each year	-27.3%	-3.4%
Moderate Scenario	What you might get back after costs	CZK246,250	CZK251,750
	Average return each year	-1.5%	0.1%
Favourable Scenario	What you might get back after costs	CZK284,000	CZK295,750
	Average return each year	13.6%	3.4%

The figures shown include all the costs of the product itself, but may or may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

In the event that the fund history is insufficient for the scenario calculation, a suitable benchmark (proxy) will be used.

Favourable scenario: this type of scenario occurred for an investment between 31/03/2020 and 31/03/2025.

Moderate scenario: this type of scenario occurred for an investment between 30/09/2021 and 24/09/2026

Unfavourable scenario: this type of scenario occurred for an investment between 31/10/2017 and 31/10/2022 .

What happens if CPR Asset Management is unable to pay out?

A separate pool of assets is invested and maintained for each Sub-Fund of CPR Invest. The assets and liabilities of the Sub-Fund are segregated from those of other sub-funds as well as from those of the Management Company, and there is no cross-liability among any of them. The Sub-Fund would not be liable if the Management Company or any delegated service provider were to fail or default.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

COSTS OVER TIME

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- CZK 250,000 invested.

Investment CZK 250,000		
Scenarios	If you exit after	
	1 year	5 years*
Total Costs	CZK15,706	CZK29,958
Annual Cost Impact**	6.4%	2.4%

* Recommended holding period.

** This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 2.54% before costs and 0.14% after costs.

These figures include the maximum distribution fee that the person selling you the product may charge (5.00% of amount invested / 12,500 CZK). This person will inform you of the actual distribution fee.

If you are invested in this product as part of an insurance contract, the costs shown do not include additional costs that you could potentially bear.

COMPOSITION OF COSTS

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	This includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge.	Up to 12,500 CZK
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	0.00 CZK
Ongoing costs taken each year		
Management fees and other administrative or operating costs	1.15% of the value of your investment per year. This percentage is an estimate.	2,731.25 CZK
Transaction costs	0.20% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	475.00 CZK
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	0.00 CZK

How long should I hold it and can I take money out early?

Recommended holding period: 5 years, which corresponds to the maturity of the product.The Sub-Fund is designed to be held until its Maturity Date; you should be prepared to stay invested until maturity. If you sell prior to the Maturity Date of the Sub-Fund an exit fee may be payable and the performance or risk of your investment may be negatively impacted. Please refer to the section 'What are the costs', for information on the costs and the impact over time if you sell prior to the Maturity Date.

Order schedule: Orders to redeem shares must be received before 02:00 PM Luxembourg time on the Valuation Day. Please refer to the CPR Invest Prospectus for further details regarding redemptions.

To manage liquidity risks, if redemption requests exceed a predefined threshold, the management company may cap redemptions (known as "gates") and process such requests only partially, on a pro-rata basis.

To ensure an equitable allocation of portfolio adjustment costs, the management company may employ a predetermined mechanism to adjust the net asset value by applying a factor reflecting liquidity costs (known as "swing pricing").

The functioning for these mechanisms are further described in the prospectus.

You may exchange shares of the Sub-Fund for shares of other sub-funds of CPR Invest in accordance with the CPR Invest prospectus.

How can I complain?

If you have any complaints, you may:

- Mail CPR Asset Management at 91-93 boulevard Pasteur, 75015 Paris, France
- E-mail to client.servicing@cpram.com

In the case of a complaint you must clearly indicate your contact details (name, address, phone number or email address) and provide a brief explanation of your complaint. More information is available on our website www.cpram.com.

If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

Other Relevant Information

You may find the prospectus, statutes, key investor documents, notices to investors, financial reports, and further information documents relating to the Sub-Fund including various published policies of the Sub-Fund on our website www.cpram.com. You may also request a copy of such documents at the registered office of the Management Company.

Past performance: There is insufficient data to provide a useful indication of past performance to retail investors.

Performance scenarios: You can find previous performance scenarios updated on a monthly basis at www.cpram.com.

Informace o rizikovosti a nákladovosti investičního produktu


V tomto dokumentu nalezne investor informace týkající se hodnocení rizika a výnosu investičního produktu a dále souhrnný odhad nákladů a poplatků souvisejících se správou produktu a pořízením a ukončením investice. Struktura uveřejněných informací vychází ze směrnice o trzích a finančních nástrojích (MIFID II).

1 Hodnocení rizika a výnosu

Hodnocení rizika a výnosu investičního produktu je prezentováno prostřednictvím syntetického ukazatele rizika (SRI).

Hodnota ukazatele vychází z historických dat a nemusí být spolehlivým vodítkem při pohledu do budoucnosti. Hodnota ukazatele se v průběhu času může změnit.

Název produktu (ISIN)	Doporučený investiční horizont (v letech)	Ukazatel rizika (SRI)
CPR Invest - B&W European Strategic Autonomy HY 2032 - A CZKH Acc LU3516173575	5,0	2



2 Souhrnný odhad nákladů a poplatků souvisejících se správou produktu a pořízením a ukončením investice.

Informace o nákladech a poplatcích jsou rozkryty, aby zákazník porozuměl celkovým nákladům a jejich možnému souhrnnému dopadu na návratnost investice. Struktura uveřejněných informací vychází ze směrnice o trzích a finančních nástrojích (MIFID II). Celkový dopad nákladů na investici klienta je zpravidla nižší.

		Odhad ročních nákladů při předpokládané investici 250 000 Kč	
CPR Invest - B&W European Strategic Autonomy HY 2032 - A CZKH Acc		v %	v Kč
Jednorázové náklady	Vstupní poplatek (nejvyšší možná částka, která může být účtována distributorem před uskutečněním investice)*	2,00%	5 000,00 Kč
	Výstupní poplatek (nejvyšší možná částka, která může být účtována distributorem před uskutečněním investice)*	0,00%	- Kč
Průběžné náklady	Celková nákladovost (počítáno dle MIFID II ex ante, jiné než v KID)**	1,15%	2 875,00 Kč
	Z toho manažerský poplatek	1,00%	2 500,00 Kč
	Transakční náklady (průměrné náklady na nákup a prodej aktiv do fondu)	0,20%	500,00 Kč
	Výkonnostní poplatek	0,00%	- Kč
Pobídka distributorovi hrazená z jednorázových nákladů		2,00%	5 000,00 Kč
Pobídka distributorovi hrazená z průběžných nákladů		0,70%	1 750,00 Kč
Celkové náklady za držení produktu během prvního roku investice		3,35%	8 375,00 Kč
Průměrné roční náklady za doporučený investiční horizont (p.a.)		1,75%	4 375,00 Kč

Reálný dopad nákladů na výkonnost konkrétní investice může být nižší. Zobrazené jednorázové náklady uvádějí maxima, které mohou být účtovány distributorem.

* Případný vstupní a výstupní poplatek se řídí platným ceníkem. Vstupní poplatek při investici nad 250.000 CZK se uplatňuje ve výši 1,5 %.

** Náklady produktu (Celková nákladovost) představují Poplatky za vedení a jiné správní nebo provozní náklady. Ve Statutu může být označeno pojmem Celková nákladovost.

Amundi Czech Republic, investiční společnost, a.s.
společnost skupiny Amundi
Rohanské nábřeží 693/10, Praha 8, 180 00, Česká republika
E-mail: infocr@amundi.com, www.amundi.cz a www.amundi-kb.cz